US Bancorp
ADVM

US Bancorp’s Adverum Biotechnologies ADVM Stock Holding History

US Bancorp’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-56
Closed -$2K – 4059
2021
Q2 		$2K Buy
56
+37
+195% +$1.99K ﹤0.01% 3792
2021
Q1 		$2K Hold
19
– – ﹤0.01% 3675
2020
Q4 		$2K Hold
19
– – ﹤0.01% 3548
2020
Q3 		$2K Hold
19
– – ﹤0.01% 3467
2020
Q2 		$4K Buy
+19
New +$3.37K ﹤0.01% 3354

Other funds holding ADVM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

US Bancorp's ADVM Position: Q3 2021 in Review

US Bancorp sold out of Adverum Biotechnologies (ADVM) in Q3 2021, closing a stake of 56 shares — an estimated $2K sold.

US Bancorp first reported a position in ADVM in Q2 2020 and held it in 5 quarters. The position peaked at $4K in Q2 2020. 110 funds tracked by Wall St. Rank hold ADVM as of Q3 2021.

  • US Bancorp reported no remaining Adverum Biotechnologies position as of Q3 2021 after selling out during the quarter.
  • US Bancorp sold 56 Adverum Biotechnologies shares in Q3 2021, an estimated $2K.
  • US Bancorp first reported a position in Adverum Biotechnologies in Q2 2020 and held it in 5 quarters.
  • US Bancorp's Adverum Biotechnologies position peaked at $4K in Q2 2020.
  • 110 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2021.

Based on US Bancorp's 13F filing for Q3 2021, filed 10 Nov 2021.